XNAS
TRNS
Market cap808mUSD
Oct 08, Last price
86.40USD
1D
-2.69%
1Q
-2.27%
Jan 2017
700.00%
Name
Transcat Inc
Chart & performance
P/E
150.43
P/S
2.44
EPS
0.57
Div yield, %
—
Shrs. gr., 5y
4.07%
Rev. gr., 5y
7.56%
Revenues
332m
+19.20%
Net income
5m
-62.96%
CFO
35m
-10.61%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Transcat, Inc. is a provider of accredited calibration and laboratory instrument services, and a value-added distributor of professional grade test, measurement, and control instrumentation. The company operates through two segments, Service and Distribution, and focuses on providing services and products to highly regulated industries, particularly the life science industry, which includes pharmaceutical, biotechnology, and medical device businesses.
Key people
Lee D. Rudow
President, Chief Executive Officer, Director · since 2015
Michael J. Tschiderer
Chief Financial Officer, Vice President of Finance, Treasurer, Corporate Secretary · since 2015
Andrew J. Quaranto
Vice President - IT · since 2019
Michael W. West
Vice President of Inside Sales and Marketing · since 2014
Scott Deverell
Principal Accounting Officer, Corporate Controller · since 2016
Jennifer J. Nelson
Vice President of Human Resources · since 2015
Oksana S. Dominach
Director · since 2019
Richard J. Harrison
Independent Director · since 2004
Gary J. Haseley
Independent Director · since 2017
Paul D. Moore
Independent Director · since 2001
Independent Director · since 2017
Alan H. Resnick
Independent Director · since 2004
Legal address
C/O CORPORATION SERVICE COMPANY
1160 DUBLIN ROAD
SUITE 400
COLUMBUS, OH 43215
US
1160 DUBLIN ROAD
SUITE 400
COLUMBUS, OH 43215
US
Headquarters
1160 DUBLIN ROAD
COLUMBUS, OH 43215
US
COLUMBUS, OH 43215
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2024‑03 | 2023‑03 | 2023‑03 | 2022‑03 | 2022‑03 | 2021‑03 | 2021‑03 | 2020‑03 | 2020‑03 | 2019‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2017‑03 | |
| Income | |||||||||||||||||
Revenues | |||||||||||||||||
Cost of revenue | |||||||||||||||||
Unusual Expense (Income) | |||||||||||||||||
NOPBT | |||||||||||||||||
NOPBT Margin | |||||||||||||||||
Operating Taxes | |||||||||||||||||
Tax Rate | |||||||||||||||||
NOPAT | |||||||||||||||||
Net income | |||||||||||||||||
Dividends | |||||||||||||||||
Dividend yield | |||||||||||||||||
Proceeds from repurchase of equity | |||||||||||||||||
BB yield | |||||||||||||||||
| Debt | |||||||||||||||||
Debt current | |||||||||||||||||
Long-term debt | |||||||||||||||||
Deferred revenue | |||||||||||||||||
Other long-term liabilities | |||||||||||||||||
Net debt | |||||||||||||||||
| Cash flow | |||||||||||||||||
Cash from operating activities | |||||||||||||||||
CAPEX | |||||||||||||||||
Cash from investing activities | |||||||||||||||||
Cash from financing activities | |||||||||||||||||
FCF | |||||||||||||||||
| Balance | |||||||||||||||||
Cash | |||||||||||||||||
Long term investments | |||||||||||||||||
Excess cash | |||||||||||||||||
Stockholders' equity | |||||||||||||||||
Invested Capital | |||||||||||||||||
ROIC | |||||||||||||||||
ROCE | |||||||||||||||||
| EV | |||||||||||||||||
Common stock shares outstanding | |||||||||||||||||
Price | |||||||||||||||||
Market cap | |||||||||||||||||
EV | |||||||||||||||||
EBITDA | |||||||||||||||||
EV/EBITDA | |||||||||||||||||
Interest | |||||||||||||||||
Interest/NOPBT | |||||||||||||||||